Research Analysts’ Weekly Ratings Updates for Option Care Health (OPCH)

Several analysts have recently updated their ratings and price targets for Option Care Health (NASDAQ: OPCH):

• 5/6/2026 – Option Care Health was given a new $28.00 price target by Morgan Stanley.
• 5/6/2026 – Option Care Health had its “overweight” rating reaffirmed by Morgan Stanley.
• 5/4/2026 – Option Care Health had its price target lowered by JPMorgan Chase & Co. from $40.00 to $33.00. They now have an “overweight” rating on the stock.
• 5/1/2026 – Option Care Health was given a new $30.00 price target by Truist Financial Corporation.
• 5/1/2026 – Option Care Health had its price target lowered by Barrington Research from $42.00 to $32.00. They now have an “outperform” rating on the stock.
• 5/1/2026 – Option Care Health had its price target lowered by UBS Group AG from $45.00 to $39.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Option Care Health was given a new $30.00 price target by Stephens.
• 5/1/2026 – Option Care Health had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $26.00 price target on the stock.
• 5/1/2026 – Option Care Health had its price target lowered by TD Cowen from $37.00 to $23.00. They now have a “hold” rating on the stock.
• 5/1/2026 – Option Care Health was downgraded by Bank of America Corporation from “buy” to “neutral”. They now have a $22.00 price target on the stock.

Insider Transactions at Option Care Health

In related news, Director Timothy P. Sullivan purchased 24,154 shares of the stock in a transaction dated Thursday, May 7th. The shares were acquired at an average cost of $20.69 per share, with a total value of $499,746.26. Following the purchase, the director directly owned 73,383 shares in the company, valued at $1,518,294.27. This trade represents a 49.06% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Harry M. Jansen Kraemer, Jr. purchased 36,610 shares of the stock in a transaction dated Monday, May 4th. The shares were bought at an average cost of $21.41 per share, for a total transaction of $783,820.10. Following the completion of the purchase, the director owned 450,000 shares in the company, valued at approximately $9,634,500. This trade represents a 8.86% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 73,264 shares of company stock valued at $1,548,316 in the last ninety days. 1.70% of the stock is currently owned by company insiders.

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.